Previous 10 | Next 10 |
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Amid surging interest in a wide swath of meme stocks today, retail investors are once again seeing traction in trading unpopular names. That said, other companies many may not necessarily associate with the meme trade are also ...
Summary Federal Reserve interest rate policy to again remain the market focus this year and create a chaotic first half. Biotechnology should be favorably positioned relative to the market if the economy slips into a recession. Biotech fortunes near term are to be determined by the ...
Summary Cassava enters 2023 much as it did 2022 - surrounded by controversy and speculation. 12 months has not been long enough to resolve the fallout from the Citizens Petition filed with the FDA last year by scientists and short sellers of Cassava stock. Cassava is filing a lawsui...
Summary Today, we put Acumen Pharmaceuticals in the spotlight for the first time. The stock of this Alzheimer's focused developmental concern is trading near its net cash on the balance sheet. An investment analysis follows in the paragraphs below. For further ...
Alzheimer’s drug developer Cassava Sciences ( NASDAQ: SAVA ) lost ~13% in the morning hours Thursday to reach the lowest level since mid-September on below-average volume amid concerns over a corporate presentation the company posted for December 2022. About ~1.2M Cassava (...
AUSTIN, Texas, Dec. 20, 2022 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA) announced today that a valued and long-time member of the Company, Nadav Friedmann, PhD, MD, has died following a brief journey with cancer, only recently discovered. “We mourn profoundly the passi...
Summary Its oral drug candidate for Alzheimer’s disease dementia has an upcoming readout. In other news, Cassava went on the legal counter-offensive against short sellers. Current evidence seems to be more in Cassava’s favor. On Dec. 06, Cassava Sciences ( SAVA...
Cassava Sciences ( NASDAQ: SAVA ) closed up ~10% Wednesday as the biotech indicated it may have open-label study data on its Alzheimer's candidate simufilam ready by the end of the year . The company said it has completed drug administration in the trial of 200 patients with m...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: Pavel Kapysh / Shutterstock.com The completion of part of an important study is pushing Cassava Sciences (NASDAQ: SAVA ) stock up today. This clinical-stage biotech company has been volatile this month but has...
Summary BioVie’s NE3107 has now shown improvement of cognition and function on different Alzheimer’s rating scales, supported by biomarkers and neuroimaging data. The data just released from a Phase 2 placebo-controlled trial in Parkinson’s disease with the same dru...
News, Short Squeeze, Breakout and More Instantly...
A look at the top 10 most actives in the United States NVIDIA Corporation (NVDA) fell 6.6% to $117.99 on volume of 383,510,118 shares Aptevo Therapeutics Inc. (APVO) rose 73.4% to $0.581 on volume of 315,289,581 shares PROSHARES TRUST (SQQQ) rose 8.7% to $8.11 on volume of 173,682,364 sha...
A look at the top 10 most actives in the United States Aptevo Therapeutics Inc. (APVO) rose 45.1% to $0.486 on volume of 64,992,551 shares Verb Technology Company Inc. (VERB) rose 3.5% to $0.1205 on volume of 54,410,242 shares NVIDIA Corporation (NVDA) fell 4.4% to $120.752 on volume of 4...
Rick Barry appointed Executive Chairman of the Board Remi Barbier resigns as President and CEO and from the Board of Directors Cassava initiates search for a new CEO AUSTIN, Texas, July 17, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA) today announced that the Boa...